BIODESIX INC (BDSX)
Health Care · Precision diagnostics / molecular oncology testing · Nasdaq
Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies.
What BIODESIX INC does
Biodesix develops and commercializes precision diagnostic tests for oncology and other disease areas. The company's tests are designed to help clinicians and biopharmaceutical companies make treatment decisions by providing molecular and phenotypic insights. Biodesix generates revenue through test sales to healthcare providers, payers, and biopharmaceutical companies, with a focus on expanding adoption and market acceptance across the healthcare ecosystem.
Themes: ["oncology diagnostics","precision medicine","liquid biopsy","clinical decision support"]
Fundamentals
- Price$21.42 as of 2026-07-10 close
- Market cap$222M as of 2026-07-13
- 1-year return+250.6% as of 2026-07-10 close
- Net margin-33.3% as of 2026-07-13
- Gross margin+82.1% as of 2026-07-13
- ROE-375.1% as of 2026-07-13
- Debt / equity5.09 as of 2026-07-13
- Revenue growth (YoY)+29.1% as of 2026-07-13
- Revenue CAGR (3y)+32.3% SEC XBRL
- Beta0.57 as of 2026-07-13
Key risks (from latest filing)
["Dependent on market adoption among payers, providers, and biopharmaceutical companies; failure to achieve significant market acceptance could limit revenue growth","History of substantial net losses ($35.3M in 2025; $497.8M accumulated deficit); company expects continued losses and may never achieve profitability","Reliance on third-party suppliers including single-source suppliers, creating vulnerability to supply disruptions and price fluctuations"]
Competitors & peers
- Guardant Health (GH)
- Foundation Medicine (acquired by Roche)
- Invitae (NVTA)
- Myriad Genetics
- GRAIL (Illumina subsidiary)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.